Can-Fite BioPharma (CANF) announced a significant new clinical finding under its compassionate use program in decompensated liver cirrhosis. The patient, previously reported by Can-Fite to have experienced the disappearance of end-stage liver disease complications while receiving Namodenoson, has now demonstrated a complete resolution of esophageal varices, as confirmed by endoscopic evaluation.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite BioPharma Reports Mid-2025 Financial Results and Drug Development Updates
- Can-Fite BioPharma reports 1H EPS 0c vs. 0c last year
- Can-Fite BioPharma Achieves Enrollment Milestone in Pancreatic Cancer Trial
- Can-Fite achieved over 50% enrollment in Phase 2a trial of Namodenoson
- Can-Fite BioPharma Raises $5 Million in Public Offering